Piper Jaffray analyst Matt O'Brien said "it is fair to wonder" if Allergan's (AGN) acquisition of Lifecell and the company's Alloderm product could be a competitive threat for Novadaq (NVDQ), though he does not expect serious pressure, arguing the company has "solid clinical data" demonstrating the benefits of its DermACELL compared to Alloderm. In fact, he would not be surprised to see Novadaq hire some "highly productive" Lifecell sales reps amid the deal shake-up and sees an opportunity to more rapidly capture share with DermACELL in the coming quarters even without salesforce defections. O'Brien, who also notes the "hefty revenue multiple" that could be placed on the DermACELL franchise as a read across from Allergan's deal, keeps an Overweight rating on Novadaq shares.